CVI and Heights disclose 9.9% Decoy Therapeutics (DCOY) warrant stake
Rhea-AI Filing Summary
Decoy Therapeutics Inc. investor reports a 9.9% passive stake. CVI Investments, Inc. and Heights Capital Management, Inc. jointly report beneficial ownership of 708,565 shares of Decoy Therapeutics common stock, all issuable upon exercise of warrants.
Their ownership represents 9.9% of the common stock, based on 6,384,177 shares outstanding as of December 26, 2025, as cited from the company’s definitive proxy statement. The warrants are subject to a 9.99% beneficial ownership cap, limiting exercise if it would push total holdings above that level. The filers certify the securities were not acquired to change or influence control of the company.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Schedule 13G/A filing reveal about Decoy Therapeutics Inc. (DCOY)?
The filing shows an institutional investor group holds a sizable passive position in Decoy Therapeutics. CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 708,565 common shares, representing 9.9% of the company based on disclosed shares outstanding.
What percentage of Decoy Therapeutics’ common stock is owned according to this Schedule 13G/A?
The reporting persons disclose beneficial ownership of 9.9% of Decoy Therapeutics’ common stock. This percentage is calculated using 6,384,177 shares outstanding as of December 26, 2025, as referenced from the company’s definitive proxy statement on Schedule 14A.
What is the beneficial ownership limitation mentioned in the Decoy Therapeutics filing?
The warrants include a 9.99% beneficial ownership limitation. They cannot be exercised to the extent that doing so would cause the reporting persons and their affiliates, together with other aggregated holders, to beneficially own more than 9.99% of Decoy’s outstanding common stock.
Do CVI Investments and Heights Capital seek to influence control of Decoy Therapeutics?
They state the securities were not acquired and are not held to change or influence control of Decoy Therapeutics. The certification specifies the holdings are not part of any control-related transaction, other than activities solely connected with a possible director nomination process under applicable rules.
Who are the reporting persons in the Decoy Therapeutics (DCOY) Schedule 13G/A?
The reporting persons are CVI Investments, Inc., organized in the Cayman Islands, and Heights Capital Management, Inc., organized in Delaware. Heights Capital serves as investment manager to CVI and may exercise shared voting and dispositive power over the reported Decoy Therapeutics warrant position.